GPBAR1 and metabolic dysfunction-associated steatohepatitis: Because adipose tissues are a major therapeutic target in NASH, and both CysLT1R and GPBAR1 are expressed in this tissue, we have then assessed how compound 2 modulates the functionality of brown and white adipose tissue (BAT and WAT) (Scheja and Heeren 2016).